Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Banerji

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
Allergy|March 29, 2014
Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working GroupM Cicardi, W Aberer, A Banerji, et al.
Aquatic Ecosystem Health & Management|May 6, 2026
Stable isotopes reveal an imprint of harmful algal blooms on Lake ErieK C Benesh, A Banerji, S A Ludsin, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 24, 2004
The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial resultsD M Reboussin, D C Goff, E W Lipkin, et al.
Diabetologia|December 17, 2009
Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) studyR A DeFronzo, M A Banerji, G A Bray, et al.
Clinical and Experimental Immunology|April 23, 2014
Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trialA Malbrán, M Riedl, B Ritchie, et al.
Diabetes, Obesity & Metabolism|April 5, 2013
Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trialG A Bray, S R Smith, M A Banerji, et al.
Allergy and Asthma Proceedings|November 23, 2017
Research abstracts presented at the Fall Meeting of the New England Society of Allergy, October 23-24, 2010, Woodstock, VermontK Issa-El-Khoury, J L Bayuk, S Patil, et al.
Allergy|April 25, 2018
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 studyM A Riedl, E Aygören-Pürsün, J Baker, et al.
Arerugi = [Allergy]|September 20, 2023
M Maurer, M Magerl, S Betschel, et al.
Arerugi = [Allergy]|May 24, 2023
M Maurer, M Magerl, S Betschel, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Allergy|March 29, 2014
Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working GroupM Cicardi, W Aberer, A Banerji, et al.
Aquatic Ecosystem Health & Management|May 6, 2026
Stable isotopes reveal an imprint of harmful algal blooms on Lake ErieK C Benesh, A Banerji, S A Ludsin, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 24, 2004
The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial resultsD M Reboussin, D C Goff, E W Lipkin, et al.
Diabetologia|December 17, 2009
Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) studyR A DeFronzo, M A Banerji, G A Bray, et al.
Clinical and Experimental Immunology|April 23, 2014
Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trialA Malbrán, M Riedl, B Ritchie, et al.
Diabetes, Obesity & Metabolism|April 5, 2013
Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trialG A Bray, S R Smith, M A Banerji, et al.
Allergy and Asthma Proceedings|November 23, 2017
Research abstracts presented at the Fall Meeting of the New England Society of Allergy, October 23-24, 2010, Woodstock, VermontK Issa-El-Khoury, J L Bayuk, S Patil, et al.
Allergy|April 25, 2018
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 studyM A Riedl, E Aygören-Pürsün, J Baker, et al.
Arerugi = [Allergy]|September 20, 2023
M Maurer, M Magerl, S Betschel, et al.
Arerugi = [Allergy]|May 24, 2023
M Maurer, M Magerl, S Betschel, et al.
Pageof 11